IP Verse

Oral Dosage Form Comprising Rifaximin In Form Beta - EP3416627

The patent EP3416627 was granted to Sandoz on Apr 22, 2020. The application was originally filed on Apr 25, 2018 under application number EP18718476A. The patent is currently recorded with a legal status of "Revoked".

EP3416627

SANDOZ
Application Number
EP18718476A
Filing Date
Apr 25, 2018
Status
Revoked
May 4, 2024
Grant Date
Apr 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFASIGMAAug 27, 2020KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1557421
DESCRIPTIONEP1698630
DESCRIPTIONWO2006094377
DESCRIPTIONWO2006094737
EXAMINATIONCN101653428
EXAMINATIONWO2009008005
INTERNATIONAL-SEARCH-REPORTCN103340856
INTERNATIONAL-SEARCH-REPORTUS2008262220
INTERNATIONAL-SEARCH-REPORTUS2011065740
INTERNATIONAL-SEARCH-REPORTWO2005044823
INTERNATIONAL-SEARCH-REPORTWO2006094737
INTERNATIONAL-SEARCH-REPORTWO2008029208
INTERNATIONAL-SEARCH-REPORTWO2009137672
INTERNATIONAL-SEARCH-REPORTWO2012038898
INTERNATIONAL-SEARCH-REPORTWO2014091432
OPPOSITIONEP1557421
OPPOSITIONEP1676847
OPPOSITIONEP2011486
OPPOSITIONEP2618819
OPPOSITIONEP2927235
OPPOSITIONWO2006094737

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AUGSBURGER; STEPHEN, Pharmaceutical Dosage Forms: Tablets, Informa Healthcare, (20080000), vol. 2-
DESCRIPTION- BRAGA et al., CrystEngComm, (20120000), vol. 14, pages 6404 - 6411-
OPPOSITION- Anonymous, "711 Dissolution", USP -NF, (20160501), pages 1 - 12, URL: https://online.uspnf.com/uspnf, XP055771101-
OPPOSITION- Anonymous, "Farmindustria associazione nazionale dellindustria farmaceutica CEDOF EDITORE - MILANO", Repertorio farmaceutico italiano, (19930000), page A-1105, XP055771200-
OPPOSITION- Anonymous, "Guideline on quality of oral modified release products", EMA European Medicines Agency - Science Medicines Health, (20140320), pages 1 - 16, XP055771110-
OPPOSITION- Anonymous, "Normix - summary of product characteristics", Normix, (20090800), pages 1 - 8, XP055771112-
OPPOSITION- Anonymous, "Tableting", Wikipedia, pages 1 - 6, XP055771128-
OPPOSITION- Budavari Susan, "Rilmazafone", The Merck Index an Encyclopedia of chemicals, drugs, and biologicals, twelfth edition, (19960000), page 8387, XP055771188-
OPPOSITION- DOTT. FABRIZIO GIORGI, "Dissolution 800mg Tablet Rifaximin B at acid PH with sodium lauryl sulphate", Experimental Report, (20200730), pages 1 - 4, XP055771108-
OPPOSITION- MAITI et al., "Introductory Chapter Drug Delivery Concepts", Advanced Technology for Delivering Therapeutics, (20170500), pages 1 - 4, XP055771174-
OPPOSITION- RUDNIC E; SCHWARTZ J B, "Oral Solid Dosage Forms", REMINGTON'S PHARMACEUTICAL SCIENCES, MACK PUBLISHING CO, US, pages 1633 - 1638, XP002969032-
OPPOSITION- W.A. RITSCHEL et al., "Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung", Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung, (20020000), pages 260 - 261, XP055771134-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents